I am very happy to share the publication of this white paper in the AAPS journal. This paper is the culmination of a significant effort as a sub team of the AAPS Biomarker and Precision medicine community that was kicked off soon after an OSD on this subject as well as a session in Biomarker 101. Many of the authors have also presented at AAPS meeting or elsewhere. I want to thank them again for the many contributions the paper; the debates and discussions, editing and refining and finally for staying the course in an effort that evolved in scope and that has spanned a number of years.
Parallelism is an essential experiment to conduct for biomarker assays but there has been limited published guidance of execution it be very can be challenging to interpret. So often the answer is "it depends". We hope this best practices paper will provide the community with sufficient information and examples to better enable biomarker scientists to execute, interpret and make appropriate decisions with parallelism data for their biomarker assay within its context of use.
Troy Voelker, Lauren Stevenson, Holly (Honglue) Shen, Marco Pepin, Rob Nelson, RJ Neely, Joel Mathews, Barry Jones, Michelle Gunsior, Fabio Garofolo, Robert Kernstock, Lakshmi Amaravadi and John Alison.
Such an incredibly strong and experienced scientific team. Reach out to any of us if you have questions or comments. We plan to have another Open Scientific Discussion based on the white paper in 2026.
Make sure to check out the case studies included in the supplemental materials as well!
------------------------------
Lindsay King Ph.D.
Executive Director
Pfizer Inc
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------